EAN signs a Memorandum of Understanding with Alzheimer Europe. Alzheimer Europe aims at  providing a voice to people with dementia and their carers, at making dementia a European priority and promote a rights-based approach to dementia. The organisation also supports… Continue Reading

EBC – European Brain Council Brain Awareness Week 2018: Expanding brain research in Europe – Education, Behavior and Brain Development 15 March 2018 – European Parliament, Strasbourg, France Co-hosted by MEPs Anne Sander (France, EPP), Daciana Sârbu (Romania, S&D) and… Continue Reading

Gunhild Waldemar (GW): Can you please tell the EAN Pages readers about the goals of the BioMed Alliance and the criteria that need to be fulfilled in order to become a member of the BioMed Alliance? Axel Pries (AP): The Association’s principal goals and objectives are to promote the best interests and values of researchers, of healthcare professionals, and of non-for-profit medical associations and organisations across all medical disciplines in Europe, in those general areas of common interest.

EAMDA is the European Alliance of Neuromuscular Disorders Associations and works to support and improve the quality of everyday life of people with neuromuscular disorders (NMDs).

    by Anna Sauerbier             EC Transparency Register The transparency register is a database that lists organisations that try to influence the law-making and policy implementation process of the EU institutions. The register makes… Continue Reading

This year the conference of French neurology residents and young neurologists (“Les journées des Jeunes Neurologues et de la Recherche Clinique, les J2N”) took place in Paris, France, on February 2-3.

Eveline Sipido: Thank you for hosting applicants of the EAN Clinical Fellowship. How would you evaluate this EAN educational opportunity? Mark Edwards (ME)/Anthony Pereira (AP): St George’s runs one of the largest Neurology & Stroke training schemes in the UK.  We cover the UK curriculum on site and so can provide a comprehensive clinical training in neurology and stroke medicine.

The next Exam of the European Board of Neurology (EBN) will take place on Friday June 15th at the EAN congress site in Lisbon. Since Prof. Wolfgang Grisold from Vienna successfully started this yearly event in 2009 we are now… Continue Reading

This year, the “History of Neuroscience Visit” will be at the Egas Moniz Museum: (€30 fee/€ 20 reduced fee) The participants of the History of Neuroscience Visit will be picked up by bus at 13.00h on Monday, June 18. All… Continue Reading

Antonio Federico (AF): Dear Professor, you founded Orphanet and gave a great contribution on the development of information about Rare Diseases in Europe. Can you summarize your past activities and the difficulties you had? Segolene Aymé (SA): That is a long story as I started to build a database of genetic diseases and of malformation syndromes described in the literature, in the mid-seventies, when I started as a clinician in medical genetics, lost in diagnosing most of the patients attending our clinic in Marseilles.

Elena Moro: Dear Prof. Vincent, you have recently been awarded with the WFN Medal for Scientific Achievement in Neurology. We congratulate with you for this well-deserved outstanding recognition! In light of your longstanding experience in the world of neuro-immunology in particular, what do you think is it the most recent important discovery in your field? Angela Vincent (AV): Well first of all thank you for the congratulations.  I am thrilled to receive the WFN Medal and it is much appreciated. Neuroimmunology is a relatively recent discipline – probably only first defined in the 1980s. 

The Republic of Lithuania is a state in northern-eastern Europe occupying 65.300 km2 area with Vilnius city as capital and a population of 2.979.000 inhabitants. Neighbors of Lithuania are Latvia, Belarus, Poland, and Russia. It is a parliamentary democracy, with… Continue Reading

As in the previous years, EANpages asked EAN committee members, panel chairs, and invited speakers  which session one should not miss at the upcoming congress in Lisbon 2018. Please find their answers below!

by Elena Moro For March 2018, we have selected: Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med 2018;378:321-330. Alzheimer’s disease (AD) pathology can be related to either excessive production or reduced elimination of beta amyloid (Aβ), which eventually results in oligomers, fibrils, and neuritic Aβ plaques.